Executive summary: US Patent 10,253,102 claims a human anti-LEPR (leptin receptor) antibody (or antigen-binding fragment) defined by a specific light-chain variable region (SEQ ID NO: 10) paired with one of three specified heavy-chain variable regions (SEQ ID NO: 2, 26, or 34). The claims also extend to (i) antibody formats (IgG1 or IgG4 with human kappa constant domains), (ii) compositions, (iii) a pen delivery device, (iv) broad “in combination with” lists across many metabolic/CNS/obesity drugs, and (v) “bispecific” embodiments. From a freedom-to-operate and enforcement perspective, independent novelty is centered on the precise VH/VL SEQ ID pairings and the particular constant-region hookups; the remaining dependent claim layers (formulation/device/combination/bispecific) materially broaden coverage but create distinct enforceability and design-around opportunities.

Caveat under your constraints: only the claim text provided is available. No bibliographic data, priority dates, prosecution history, applicant/assignee, related patents, file wrapper estoppel, terminal disclaimers, or cited art were provided. A complete “critical analysis of the claims and patent landscape” for this specific patent requires those data; without them, any definitive landscape (portfolio mapping, expiration dates, claim construction conclusions, litigation or Orange Book status) would be incomplete.

US Patent 10,253,102: claims and patent landscape for human anti-LEPR antibodies binding SEQ ID NO: 10 with SEQ ID NO: 2/26/34

What do claims 1-3 of US 10,253,102 cover for anti-LEPR antibody specificity?

Answer: They cover isolated antibodies or binding fragments to human LEPR defined by a strict variable-region pairing:

VL: light chain variable region comprises SEQ ID NO: 10
VH: heavy chain variable region comprises one of:
- SEQ ID NO: 2
- SEQ ID NO: 26
- SEQ ID NO: 34
  Claim 1 further specifies that the antibody “comprises the light chain CDRs” from the VL (SEQ ID NO: 10) and the heavy-chain CDRs from the VH (SEQ ID NO: 2/26/34). Claims 2 and 3 are structurally narrower or alternative depending on how “CDR” is treated versus the full variable sequence.

Claim-by-claim parsing

Claim 1 (broad independent covering multiple VH options via CDR framing)

Antibody/binding fragment binds human LEPR
Must include:
- Light chain CDRs of VL containing SEQ ID NO: 10
- Heavy chain CDRs of VH containing SEQ ID NO: 2 or 26 or 34

Claim 2 (sequence framing rather than explicit CDRs)

Antibody/binding fragment binds human LEPR
Must include:
- Light chain variable region: SEQ ID NO: 10
- Heavy chain variable region: SEQ ID NO: 2 or 26 or 34

Claim 3 (single VH option)

Antibody/binding fragment binds human LEPR
Must include:
- VL: SEQ ID NO: 10
- VH: SEQ ID NO: 2 only

Critical scope implications

Hard-coded SEQ ID constraints are the core novelty lever. Any design-around that changes either the VL (SEQ ID NO: 10) or the specific VH sequences is the most direct path out.
CDR-only recitation can widen scope depending on interpretation. Claim 1 uses “CDRs” rather than “variable region sequence.” If SEQ ID NO: 10 is used to define CDRs, an accused antibody could argue that its framework residues differ while retaining equivalent CDRs. Claim 2/3 pull back to full variable region sequences.
Binding to “human LEPR” is required, not cross-species binding. A non-binding or only weak/conditional binding could be outside, but that turns on assay definitions not provided.

How narrow are claims 4-14 after the SEQ ID pairing is established (IgG1 vs IgG4 constant domains)?

Answer: Claims 4-14 convert the claimed variable regions into specific full antibodies and explicitly tie heavy constant domains to human IgG1 or IgG4, and light constant domains to human kappa.

Constant-region dependencies that matter for design-around

Claim 4: antibody (not just fragment)
Claim 5: heavy constant = human IgG1, light constant = human kappa
Claim 6: heavy constant = human IgG4, light constant = human kappa
Claims 7-10: same pattern for the SEQ ID NO: 26 heavy chain pairing (in claims 7/8, then constant regions in 9/10)
Claims 11-14: same pattern for the SEQ ID NO: 34 heavy chain pairing (in claims 11/12, then constant regions in 13/14)

Critical enforcement point: even with the same VH/VL sequences, moving from IgG1/IgG4 to other constant regions (IgG2/IgG3, Fc variants, or non-kappa lights) could place an accused product outside these dependent claims. Claims 1-3 remain potentially broader if they cover antigen-binding fragments or unspecified constant regions, but you did not provide claim 1’s constant-region limitations.

What do claims 15-17 cover in pharmaceutical composition protection?

Answer: They cover a pharmaceutical composition containing the claimed antibody (as per the corresponding SEQ ID pairing) plus a pharmaceutically acceptable carrier/diluent.

Practical implications

These are typical “composition of matter” or “composition” claims that are usually easier to satisfy for infringement if the antibody is used in any conventional formulation.
Design-around generally shifts to non-infringing antibody variants rather than formulation changes, unless the formulation enables a claim exception (not given).

How does claim 21-23 broaden IP coverage with a pen delivery device?

Answer: Claims 21-23 extend to a pen delivery device comprising the composition of claims 15-17 (and therefore, the specific antibody SEQ ID pairings).

Critical scope questions for enforceability

Pen-device claims can capture combination products even if the active antibody is used in a “ready-to-inject” style format.
Design-around could focus on:
- a different delivery system (autoinjector, vial+needle, pump)
- a different device platform not meeting the claim language for “pen delivery device”
Without device claim definition (features, structural elements, or claims construction), coverage strength is difficult to quantify.

What is the risk created by claims 24-26 “in combination with” broad drug lists?

Answer: They attempt to cover the claimed anti-LEPR antibody used alongside a long list of therapeutics spanning obesity/metabolic agents, lipid-lowering drugs, antidiabetics, GLP-1 pathway drugs, and CNS/metabolic combinations.

Claim 24-26 structure

Claim 24: antibody of claim 4 (IgG format tied to SEQ ID NO: 10 + VH=SEQ ID NO: 2 depending on the chain of dependencies in your text) + one or more additional therapeutically active components from the list
Claim 25: antibody of claim 8 (corresponding to VH=SEQ ID NO: 26) + same list
Claim 26: antibody of claim 12 (corresponding to VH=SEQ ID NO: 34) + same list

Critical breadth assessment

Combination claim breadth is extremely high. The enumerated list is long enough that it likely overlaps many real-world combination regimens for obesity, diabetes, hyperlipidemia, and appetite/metabolic control.
Litigation posture: combination claims can be powerful against product marketers who sell co-formulated or co-packaged combination regimens. They can be harder to enforce if the patent holder must prove the accused product is marketed/used “in combination with” a listed agent.
Design-around via “not in combination.” If an infringer avoids co-administration or co-marketing with listed agents, they may seek to avoid literal combination coverage. That depends on how the claims are construed (co-formulation vs concurrent therapy).

Notable items in the list (as provided)

The list includes antibodies alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab and a range of small molecules including statins (atorvastatin through others), ezetimibe, insulin, metformin, SGLT2 inhibitors (dapagliflozin/canagliflozin/empagliflozin), incretin agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide), and multiple CNS/metabolic agents (phentermine, topiramate, bupropion, naltrexone, zonisamide), plus other receptor-targeting antibodies (anti-GCG, anti-GCGR, anti-ANGPTL3/4/8).

What does “bispecific” coverage add in claims 27-29?

Answer: Claims 27-29 extend to antibodies of the relevant SEQ ID pairing that are bispecific.

Critical enforcement and design-around implications

Bispecific constructs often differ in architecture (dual targets, half-life extension, one-arm vs two-arm designs). Claim 27-29 are drafted broadly, but “bispecific” is an architecture term that courts construe based on whether two binding specificities are present and how the molecule is constructed.
Design-around could attempt to remain monovalent for LEPR while adding other functionalities without becoming bispecific, or choose an alternate bispecific architecture that arguably falls outside the claim definition (not determinable from the provided text alone).

How strong is the patent estate for US 10,253,102 based on the claim architecture alone?

Answer: Strength is concentrated in the SEQ ID-defined variable regions. Dependent layers broaden coverage into formats (IgG1/IgG4), formulations, delivery devices, combinations, and bispecific constructions.

Strength factors implied by the claim set

Definite sequence identity requirements (SEQ ID NO: 10 and VH SEQ ID choices) reduce ambiguity and strengthen infringement mapping for sequence-defined antibodies.
CDR-based language in claim 1 can increase coverage in cases where accused antibodies use different frameworks but preserve the same CDR sequences.
Device and combination dependencies add commercial leverage, potentially reaching packaged regimens and branded injection systems.

Weakness or volatility implied

Overbreadth risk for combination claims: proving “in combination with” a particular enumerated agent can become a factual inquiry tied to labeling, clinical use, and co-administration practices.
Bispecific ambiguity: without clear definitions of bispecific architecture in the provided text, “bispecific” can become a contested claim construction issue.
Constant-region dependencies provide easy design-around if an infringer swaps constant domains and the asserted claim is limited to IgG1 or IgG4.

What patent landscape issues are most relevant to analyzing US 10,253,102 without bibliographic and litigation data?

Answer: The following are the highest-value landscape axes to map, based strictly on what the claims themselves indicate.

Which other patents likely cover the same SEQ ID antibodies or adjacent LEPR epitope variants?

Even without knowing the applicant, LEPR-antibody families typically cluster around:

alternative VH partners paired with the same VL
alternative VL partners with the same VH
different constant regions (IgG1, IgG4, engineered Fc)
epitope binning variants (overlapping vs distinct LEPR epitopes)
bispecific formats combining LEPR with another target (metabolic or immune pathways)

Your claims suggest a family logic: one VL (SEQ ID NO: 10) paired with multiple VH options (2, 26, 34) and multiple formats.

Which jurisdictions matter for enforcement vs manufacturing?

US claims cover US infringement. Operationally, generic/biosimilar-like risks for antibodies often depend on:

whether the variable sequence constraints are mirrored in other jurisdictions’ filings
whether the patent is part of a broader international family (EP/WO)
whether there are later US continuations with narrower or broader claim sets

This cannot be concluded from the provided text.

Does the combination list create overlapping coverage with other antibody or small-molecule combination patents?

Yes by design. Claim 24-26 list many approved drugs across metabolic indications. This suggests:

potential interference with other combo-regimen patents from obesity, diabetes, and lipid-management incumbents
potential licensing expectations if a competitor develops a LEPR antibody regimen together with commonly used metabolic drugs

Again, family and prosecution history are needed to confirm.

Claim-to-risk matrix for commercial development and FTO planning (based only on the provided claim text)

Development move	What claim element it hits	Infringement exposure (qualitative)
Use an LEPR antibody with different VL than SEQ ID NO: 10	Claim 1-3 depend on VL SEQ ID NO: 10	High design-around
Use the same VL SEQ ID NO: 10 but different VH sequence not equal to 2/26/34	Claim 1-3 depend on VH among SEQ ID NO: 2/26/34	High design-around
Preserve the exact SEQ ID pair but change framework residues only	Claim 2/3 require full variable region sequence; claim 1 uses CDRs	Depends on whether full variable region sequence is altered
Switch heavy constant domain from IgG1/IgG4 to another	Claims 5-6, 9-10, 13-14	Avoids those dependent claims
Formulate in a standard vial/syringe, not a pen	Claims 21-23	Avoids device-layer claims
Deliver via pen if composition includes in-claims antibody	Claims 21-23	Infringement risk rises
Market LEPR antibody as combination therapy with one of listed agents	Claims 24-26	Risk increases with co-marketing/co-administration
Avoid combination marketing with any listed agent	Claims 24-26	Potentially avoids those claims depending on facts
Create LEPR bispecific with a different bispecific architecture	Claims 27-29	Contested construction risk

Key Takeaways

The enforceable “core” of US 10,253,102 is the SEQ ID-defined variable region pairing: VL = SEQ ID NO: 10 combined with VH = SEQ ID NO: 2 or 26 or 34.
Dependent claims broaden protection into IgG1/IgG4 formats, pharmaceutical compositions, and pen delivery devices tied to those specific antibody species.
Combination claims (24-26) are commercially aggressive: they attempt to cover the LEPR antibody when used with many widely used metabolic drugs, which increases licensing and marketing pressure but also raises evidentiary issues around “in combination with” use.
Bispecific claims (27-29) widen coverage to dual-binding architectures, but “bispecific” will turn into a claim-construction and product-structure question.

FAQs

Do claims 1 vs 2 create different infringement outcomes for antibodies that retain only the CDR sequences?
Yes in principle: claim 1 emphasizes CDRs while claim 2 emphasizes full variable region sequences.
If an antibody uses SEQ ID NO: 10 and SEQ ID NO: 2 but changes to a non-IgG1/non-IgG4 constant domain, is it outside the patent?
It may avoid dependent claims that require IgG1/IgG4, but independent claims that do not restrict constant regions could still apply depending on how they are construed.
Does the “pen delivery device” limitation require a specific device structure?
It requires the device to meet the claim language for “pen delivery device,” but the specific structural elements are not provided in the claim text excerpt.
How does a “not in combination” clinical trial design affect claims 24-26 exposure?
If no co-administration/co-marketing with listed agents occurs, the factual basis for “in combination with” coverage can weaken, depending on how a court construes that phrase.
What is the biggest commercial design-around lever for a competitor?
Changing either the VL sequence (SEQ ID NO: 10) or the VH sequence away from SEQ ID NO: 2/26/34 is the most direct path away from the core claim.

References

US Patent 10,253,102 (claims provided in prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	April 15, 2014	⤷ Start Trial	2038-06-13
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 18, 2014	⤷ Start Trial	2038-06-13
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 04, 2020	⤷ Start Trial	2038-06-13
Amgen Inc.	REPATHA	evolocumab	Injection	125522	August 27, 2015	⤷ Start Trial	2038-06-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,253,102

Summary for Patent: 10,253,102